Preclinical Testing of PI3K Inhibitors for Vestibular Schwannomas

PI3K 抑制剂治疗前庭神经鞘瘤的临床前测试

基本信息

批准号：
10447797
负责人：
CRISTINA Maria FERNANDEZ-VALLE
金额：
$ 55.7万
依托单位：
UNIVERSITY OF CENTRAL FLORIDA
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-07-01 至 2025-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10447797
关键词：
Acoustic Nerve Acoustic Neuroma Address Adult Allografting Animal Model Antineoplastic Agents Apoptosis Auditory Brainstem Responses Autophagocytosis Benchmarking Benign Benign Schwannoma Biological Assay Brain Stem Cell Cycle Arrest Cell Line Cell Proliferation Cells Child Clinical Data Clinical Trials Consequentialism Cytostatics Development Disease Drug Combinations Drug Kinetics Drug Screening Drug Targeting Epidermal Growth Factor Receptor Equilibrium Evaluation Excision FDA approved FRAP1 gene Facial paralysis Family Follow-Up Studies Future Genes Global Change Goals Growth Hearing Hematopoietic Neoplasms Histone Deacetylase Inhibitor Human Immunohistochemistry In Vitro Individual Label Lead Libraries Life Measures Modeling Molecular Molecular Analysis Molecular Profiling Mus Mutation Necrosis Nerve Neurilemmoma Neurofibromatosis 2 Neurofibromin 2 Operative Surgical Procedures Outcome Study Pathway interactions Patient observation Patients Pharmaceutical Preparations Pharmacotherapy Phenotype Phosphatidylinositols Phosphotransferases Play Preclinical Testing Preparation Radiation Radiation therapy Rattus Reporting Robotics Rodent Role Schwann Cells Signal Pathway Solid Neoplasm Testing Therapeutic Translations Tumor Expansion Tumor Suppressor Genes Tumor Suppressor Proteins Work Xenograft Model Xenograft procedure bevacizumab bilateral vestibular Schwannoma cancer clinical trial comparative efficacy cytotoxic deafness drug candidate drug development drug efficacy drug mechanism druggable target efficacy evaluation efficacy testing hearing impairment hearing loss risk hearing preservation high throughput screening in vivo inhibitor kinase inhibitor lapatinib leukemia loss of function nanomolar novel off-label use pre-clinical preclinical evaluation preservation prevent progressive hearing loss research clinical testing response sciatic nerve screening standard care transcriptome transcriptome sequencing tumor

项目摘要

ABSTRACT Mutations in the merlin (NF2) tumor suppressor gene cause the benign tumor disorder, Neurofibromatosis type 2 (NF2). This disorder predisposes individuals to develop bilateral vestibular schwannomas (VS) that cause progressive hearing loss and can cause life-threatening brainstem compression. Because surgical removal of a VS often causes deafness, facial paralysis, and imbalance, there is a need to develop drug therapies to slow or prevent VS growth and preserve nerve function. We have worked to establish an in vitro and in vivo drug screening platform to identify novel compounds as well as FDA-approved drugs that can be developed/repurposed for VS therapies. Toward this goal, we have created mouse and human merlin-deficient Schwann cell lines and optimized their use in 384-well high-throughput and high-content assays in order to screen large compound/drug libraries using robotic platforms. This approach identified several phosphoinositide- 3 kinase (PI3K) inhibitors that selectively reduce viability of mouse merlin-deficient compared to wild-type Schwann cells with nanomolar IG50. This initial finding was confirmed in human merlin-deficient Schwann cell lines for multiple PI3K, dual PI3K/mTOR and PI3K/HDAC inhibitors. Because PI3K plays a critical role in cell proliferation, survival, and invasion, there are currently 15 different PI3K inhibitors in clinical trials for various blood cancers and solid tumors. The first in class PI3K inhibitor (idelalisib) was approved in 2014 for leukemia. In this proposal, we advance our findings by conducting a systematic screen of PI3K pathway inhibitors in vitro and in vivo. The aims of this proposal are to: 1) profile a library of PI3K pathway inhibitors for efficacy in reducing viability of human merlin-deficient Schwann cell lines and primary human VS cells; 2) test efficacy of the advanced PI3K inhibitors to slow graft expansion and preserve hearing and balance in a novel rat xenograft model, and 3) conduct phenotypic, kinome, and transcriptome analysis to reveal the molecular signatures and adaptive changes of the cells and grafts to the inhibitors. We expect to obtain the necessary pre-clinical data to support the potential use of PI3K inhibitors in patients with NF2-associated VS.

抽象的 merlin (NF2) 肿瘤抑制基因突变导致良性肿瘤疾病，神经纤维瘤病型 2（NF2）。这种疾病使个体容易出现双侧前庭神经鞘瘤 (VS)，从而导致进行性听力丧失，并可能导致危及生命的脑干受压。因为手术切除了 VS经常引起耳聋、面瘫和失衡，需要开发药物疗法来减缓或防止 VS 生长并保护神经功能。我们致力于建立一种体外和体内药物筛选平台，用于识别新化合物以及 FDA 批准的药物为 VS 疗法开发/重新利用。为了实现这一目标，我们创造了小鼠和人类 Merlin 缺陷型小鼠雪旺细胞系并优化了它们在 384 孔高通量和高内涵测定中的使用，以便使用机器人平台筛选大型化合物/药物库。该方法鉴定了几种磷酸肌醇与野生型相比，3 种激酶 (PI3K) 抑制剂可选择性降低 merlin 缺陷型小鼠的活力具有纳摩尔级 IG50 的雪旺细胞。这一初步发现在人类 merlin 缺陷型雪旺细胞中得到证实多种 PI3K、双 PI3K/mTOR 和 PI3K/HDAC 抑制剂系列。因为PI3K在细胞中起着至关重要的作用增殖、存活和侵袭，目前有 15 种不同的 PI3K 抑制剂处于临床试验中，用于各种血癌和实体瘤。第一个 PI3K 抑制剂 (idelalisib) 于 2014 年被批准用于治疗白血病。在本提案中，我们通过在体外对 PI3K 通路抑制剂进行系统筛选来推进我们的发现和体内。该提案的目的是：1）分析 PI3K 通路抑制剂库，以有效减少人类 merlin 缺陷型雪旺细胞系和原代人类 VS 细胞的活力； 2）测试功效先进的 PI3K 抑制剂可减缓新型大鼠异种移植物的移植物扩张并保持听力和平衡模型，3) 进行表型、激酶组和转录组分析，以揭示分子特征和细胞和移植物对抑制剂的适应性变化。我们期望获得必要的临床前数据支持 PI3K 抑制剂在 NF2 相关 VS 患者中的潜在用途。

项目成果

期刊论文数量（1）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

WP1066 induces cell death in a schwannomatosis patient-derived schwannoma cell line.

WP1066 诱导神经鞘瘤病患者来源的神经鞘瘤细胞系的细胞死亡。

DOI：
发表时间：
2022-06
期刊：
影响因子：
1.8
作者：
Allaf, Abdulrahman;Victoria, Berta;Rosario, Rosa;Misztal, Carly;Humayun Gultekin, Sakir;Dinh, Christine T;Fernandez
通讯作者：
Fernandez